Novartis AG (NVS) Given Average Rating of “Hold” by Analysts

Novartis AG (NYSE:NVS) has been given a consensus recommendation of “Hold” by the eighteen research firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $83.19.

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th. UBS Group reiterated a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th.

Novartis (NVS) traded up $0.26 during midday trading on Friday, reaching $93.91. The company had a trading volume of 1,944,308 shares, compared to its average volume of 1,210,000. Novartis has a 1 year low of $71.50 and a 1 year high of $94.19. The stock has a market capitalization of $245,960.00, a P/E ratio of 28.90, a PEG ratio of 2.48 and a beta of 0.74. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.81.

Novartis (NYSE:NVS) last released its earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The firm had revenue of $12.92 billion for the quarter, compared to the consensus estimate of $12.65 billion. During the same period in the prior year, the business posted $1.14 earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. sell-side analysts predict that Novartis will post 5.3 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in NVS. Janus Henderson Group PLC raised its holdings in shares of Novartis by 42,797.5% in the 2nd quarter. Janus Henderson Group PLC now owns 1,914,516 shares of the company’s stock worth $159,821,000 after purchasing an additional 1,910,053 shares during the period. Parnassus Investments CA raised its holdings in shares of Novartis by 18.5% during the 3rd quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock valued at $811,095,000 after buying an additional 1,477,168 shares during the period. FMR LLC raised its holdings in shares of Novartis by 172.1% during the 2nd quarter. FMR LLC now owns 2,294,782 shares of the company’s stock valued at $191,546,000 after buying an additional 1,451,441 shares during the period. BlackRock Inc. raised its holdings in shares of Novartis by 25.3% during the 2nd quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock valued at $296,299,000 after buying an additional 717,186 shares during the period. Finally, Bain Capital Public Equity Management LLC purchased a new stake in shares of Novartis during the 2nd quarter valued at about $45,845,000. Institutional investors own 10.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://stocknewstimes.com/2018/02/11/novartis-ag-nvs-given-average-rating-of-hold-by-analysts.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply